Search

Your search keyword '"Xia, Yuanshi"' showing total 18 results
Start Over Author "Xia, Yuanshi"
18 results on '"Xia, Yuanshi"'

2. Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

3. Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

4. Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

5. Data from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

6. Supplementary tables 1-4 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

7. Supplementary materials and methods 1 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

8. Supplementary figures 1-4 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

9. Supplementary materials and methods 1 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

10. Supplementary figures 1-4 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, primary, Liu, Zhuojun, primary, Yang, Fan, primary, Liu, Jia, primary, Zhang, Leqiang, primary, Wu, Yajin, primary, Xia, Yuanshi, primary, Ou, Yuxuan, primary, Li, Ruiting, primary, Zhang, Ting, primary, Zhang, Jiecheng, primary, Ke, Xiaoyan, primary, Hu, Kai, primary, and Yu, Jian, primary

Published
2023
Full Text
View/download PDF

11. Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Author

Chen, Wei, primary, Shi, Hui, additional, Liu, Zhuojun, additional, Yang, Fan, additional, Liu, Jia, additional, Zhang, Leqiang, additional, Wu, Yajin, additional, Xia, Yuanshi, additional, Ou, Yuxuan, additional, Li, Ruiting, additional, Zhang, Ting, additional, Zhang, Jiecheng, additional, Ke, Xiaoyan, additional, Hu, Kai, additional, and Yu, Jian, additional

Published
2023
Full Text
View/download PDF

15. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies

Author

Yan, Weiqi, Liu, Zhuojun, Liu, Jia, Xia, Yuanshi, Hu, Kai, and Yu, Jian

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases
Abstract

T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development.

Published
2020
Full Text
View/download PDF

16. Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies

Author

Han, Yizhao, Liu, Zhuojun, Liu, Jia, Yan, Weiqi, Xia, Yuanshi, Yue, Shuhua, and Yu, Jian

Subjects
Article Subject
Abstract

As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody treatments, and CAR-T cell therapies, have displayed longer survival time and fewer adverse reactions, even though specific efficacy and safety of these antibody-based immunotherapies still need to be evaluated and improved. This review summarized the advantages of antibody-based immunotherapies over conventional treatments, as well as its existing difficulties and solutions, thereby enhancing the understanding and applications of antibody-based immunotherapies in HM treatment.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results